RT @AdvaMedUpdate: The legislation passed today "will create a pro-growth environment that allows America's #medtech industry to maintain i….

We look forward to continuing our work with the President and his administration and leaders on both sides of the Capitol who understand this vital policy dynamic. 7/7.

Supporting policies that lower the cost of doing business and opposing policies that raise the cost are essential to ensuring U.S. medtech’s expanding global leadership role. 6/.

The steady and competitive corporate tax rate provides much-needed certainty for our companies as they plan for the future. Seventy percent of the medtech used in America is made in America, and medtech jobs have grown at more than three times the average since TCJA. 5/.

Expansion of QSBS will support early-stage companies trying to raise capital and hire talent, which is critical to getting groundbreaking medtech developments into the hands of doctors and their patients. 4/.

The R&D and capital investment expensing provisions, for example, will spur even greater medtech R&D from our fast-moving innovators. 3/.

“The U.S. medical technology industry leads the world in innovation and manufacturing, filling our hospitals and clinics with American-engineered and -manufactured technologies that improve and save lives every minute of every day. 2/.

We thank Pres. @realDonaldTrump, @VP Vance, @LeaderJohnThune, @SpeakerJohnson, Chair @MikeCrapo & Chair @JasonSmithMO for the legislation passed today that will without question create a pro-growth environment for America’s #medtech industry to maintain its global leadership. 1/7.

This is a bold vision—and #medtech is already leading to achieve it. I’ve seen it firsthand with our Type-1 diabetic daughter: Putting patients in the driver’s seat with clear, instant data on their own vitals? It’s game changing and life saving.

Great interview on @FoxBusiness with @jeffdilullo of @Philips. Philips is doing remarkable work all around, but the focus here was on the incredible promise of #AI for better patient outcomes, ending with an important discussion of tariffs:.

I testified in the Senate today on the impact tariffs are having on the #medtech supply chain. We support the President's goals to restore U.S. manufacturing & fix trade imbalances, but here's why medtech is unique when it comes to tariffs:.

Looking forward to testifying before the Senate Finance Committee on the impact of trade and tariff policy on #medtech and the patients our industry serves .

Randy Rutta & the entire NHC team are doing tremendous work to amplify the voices of the millions of people living with chronic diseases & disabilities in the U.S. We at @AdvaMedUpdate are proud to be partners! 2/2.

Great discussion at the @NHCouncil's Science of Patient Engagement Symposium! Thanks to Dr. Espinoza Salomon, Christine Waggoner, and Karl Cooper, for the insights they shared on this panel & their leadership overall on empowering patients in our health care system. 1/1

2/2 We appreciate the flexibility he is showing with tariff policy and support the recent announcement that certain consumer products like smartphones and computers will be protected. Here is why #medtech deserves the same flexibility:.

1/2 President Trump’s goal to correct longstanding trade imbalances and bring more manufacturing back to America is a worthy one. And his decision to pause reciprocal #tariffs until July as he negotiates with countries to achieve this balance was a wise one.

Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the #medtech industry is protected, with the hope that the ultimate outcome is “zero for zero” #tariffs on medtech with all key trading partners. 2/2.

We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally. 1/2.

Dr. Makary has made clear he is committed to building a stronger, more transparent, & "smarter FDA that works for all Americans." That has long been our top objective for the patients our companies serve, and we look forward to working with him to achieve exactly that. 5/5.

And second, to ensure FDA remains the global gold standard for its rigorous medical device safety and efficacy standards. An efficient, transparent FDA is key to both goals. 4/.